Trandolapril NDC 68180-566

NDC codes

FDA NDC Directory

Product NDC (as listed)68180-566Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68180-0566Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68180-566-01	68180056601	100 TABLET in 1 BOTTLE (68180-566-01)Marketed from Jun 11, 2007

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Trandolapril
Generic name (nonproprietary): trandolapril
Active ingredients: Trandolapril — 1 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Lupin Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 077522
Marketing start: Jun 11, 2007
Listing expires: Dec 31, 2026
Other FDA classes: Angiotensin-converting Enzyme Inhibitors (Mechanism)
Identifiers: Product ID 68180-566_97cefaf3-9c1f-43e3-a30c-e9631872a8e8SPL ID 97cefaf3-9c1f-43e3-a30c-e9631872a8e8SPL set ID 8143a6cf-dadc-4ef7-a8db-d16d7150ad34RxCUI 199351, 199352, 199353UNII 1T0N3G9CRC
Pharmacologic class: Angiotensin Converting Enzyme Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N468180056601 followed by a unit qualifier and the quantity

Package 68180-0566-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 31, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE Hypertension Trandolapril tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. Heart Failure Post Myocardial Infarction or Left-Ventricular Dysfunction Post Myocardial Infarction Trandolapril tablets are indicated in stable patients who have evidence of left-ventricular systolic dysfunction (identified by wall motion abnormalities) or who are symptomatic from congestive heart failure within the first few days after sustaining acute myocardial infarction. Administration of trandolapril to Caucasian patients has been shown to decrease the risk of death (principal…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 077522

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 077522
Product	Strength	Form · route	Labeler	Product NDC
Trandolapril	Trandolapril 2 mg/1	TabletOral	Lupin Pharmaceuticals, Inc.	68180-567
Trandolapril	Trandolapril 4 mg/1	TabletOral	Lupin Pharmaceuticals, Inc.	68180-568
Trandolapril	Trandolapril 2 mg/1	TabletOral	Bryant Ranch Prepack	63629-8003